Table 1 Correlation between c-maf expression and disease characteristics of multiple myeloma patients
From: Clinical implications of c-maf expression in plasma cells from patients with multiple myeloma
Characteristics | All patients (n = 128) | C-maf-positive (n = 39) | C-maf-negative (n = 89) | p value |
|---|---|---|---|---|
Sex, F/M | 44/84 | 11/28 | 33/56 | 0.331 |
Age, years, n (%) | ||||
≤60 | 66 (51.6) | 20 (51.3) | 46 (51.7) | |
>60 | 62 (48.4) | 19 (48.7) | 43 (48.3) | 0.966 |
Isotype, IgH, n (%) | ||||
IgA | 31 (24.2) | 9 (23.1) | 22 (24.7) | |
IgD | 6 (4.7) | 1 (2.6) | 5 (5.6) | |
IgG | 55 (43.0) | 21 (53.8) | 34 (38.2) | |
Light chains | 36 (28.1) | 8 (20.5) | 28 (31.5) | 0.342 |
Isotype, IgL, n (%) | ||||
κ | 60 (46.9) | 17 (43.6) | 43 (48.3) | |
λ | 68 (53.1) | 22 (56.4) | 46 (51.7) | 0.622 |
D–S stage, n (%) | ||||
1A + 2A | 14 (10.9) | 2 (5.1) | 12 (13.5) | |
3A | 85 (66.4) | 30 (76.9) | 55 (61.8) | |
3B | 29 (22.7) | 7 (17.9) | 22 (24.7) | 0.176 |
ISS stage, n (%) | ||||
I + II | 72 (56.3) | 20 (51.3) | 52 (58.4) | |
III | 56 (43.8) | 19 (48.7) | 37 (41.6) | 0.453 |
Alb level, n (%) | ||||
≥35 g/L | 65 (50.8) | 14 (35.9) | 51 (57.3) | |
<35 g/L | 63 (49.2) | 25 (64.1) | 38 (42.7) | 0.026 |
β2-MG level, n (%) | ||||
≤2500 μg/L | 25 (19.5) | 2 (5.1) | 23 (25.8) | |
>2500 μg/L | 103 (80.5) | 37 (94.9) | 66 (74.2) | 0.007 |
Hb, n (%) | ||||
<80 g/L | 63 (49.2) | 21 (53.8) | 42 (47.2) | |
≥80 g/L | 65 (50.8) | 18 (46.2) | 47 (52.8) | 0.488 |
Plt, n (%) | ||||
≤140 × 109/L | 62 (48.4) | 20 (51.3) | 42 (47.2) | |
>140 × 109/L | 66 (51.6) | 19 (48.7) | 47 (52.8) | 0.670 |
Calcium level, n (%) | ||||
≤2.54 mmol/L | 110 (85.9) | 35 (89.7) | 75 (84.3) | |
>2.54 mmol/L | 18 (14.1) | 4 (10.2) | 14 (15.7) | 0.412 |
CRP level, n (%) | ||||
≤8.0 mg/L | 92 (71.9) | 29 (74.4) | 63 (70.8) | |
>8.0 mg/L | 36 (28.1) | 10 (25.6) | 26 (29.2) | 0.679 |
LDH level, n (%) | ||||
≤250 U/L | 105 (82.0) | 31 (79.5) | 74 (79.8) | |
>250 U/L | 23 (18.0) | 8 (20.5) | 15 (20.2) | 0.620 |